Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect of Troglitazone on Thermal Sensitivity in Uterine Cervix Cancer Cells

자궁 경부암 세포에서 Troglitazone이 온열감수성에 미치는 영향

  • Lee, Ji-Hye (Department of Radiation Oncology, Chungbuk National University College of Medicine) ;
  • Kim, Won-Dong (Department of Radiation Oncology, Chungbuk National University College of Medicine) ;
  • Yu, Jae-Ran (Department of Environmental and Tropical Medicine, Konkuk University College of Medicine) ;
  • Park, Woo-Yoon (Department of Radiation Oncology, Chungbuk National University College of Medicine)
  • 이지혜 (충북대학교 의과대학 방사선종양학교실) ;
  • 김원동 (충북대학교 의과대학 방사선종양학교실) ;
  • 유재란 (건국대학교 의과대학 환경생물의학교실) ;
  • 박우윤 (충북대학교 의과대학 방사선종양학교실)
  • Received : 2010.04.30
  • Accepted : 2010.06.03
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Troglitazone (TRO), a PPAR-$\gamma$ agonist, can reduce heat shock protein (HSP) 70 and increase the antioxidant enzymes, such as superoxide dismutase (SOD) and catalase, which might affect thermal sensitivity. Here, we investigated whether TRO modifies thermal sensitivity in uterine cervical cancer cells, which is most commonly treated by hyperthermia (HT). Materials and Methods: HeLa cells were treated with $5{\mu}M$ TRO for 24 hours before HT at $42^{\circ}C$ for 1 hour. Cell survival was analyzed by clonogenic assay. The expression of HSPs was analyzed by Western blot. SOD and catalase activity was measured and reactive oxygen species (ROS) was measured using 2',7'-dichlorofluorescin diacetate and dihydroethidium. Results: The decreased cell survival by HT was increased by preincubation with TRO before HT. Expression of HSP 70 was increased by HT however, it was not decreased by preincubation with TRO before HT. The decreased Bcl-2 expression by HT was increased by preincubation with TRO. SOD and catalase activity was increased by 1.2 and 1.3 times,respectively with TRO. Increased ROS by HT was decreased by preincubation with TRO. Conclusion: TRO decreases thermal sensitivity through increased SOD and catalase activity, as well as scavenging ROS in HeLa cells.

목 적: Troglitazone (TRO)은 PPAR-$\gamma$ 작동제로서 온열감수성의 결정에 중요한 요인인 heat shock protein (HSP) 70의 합성을 저해하고 superoxide dismutase (SOD)와 카타라제를 증가시키는 것으로 알려져 있다. 이에 자궁경부암 세포를 대상으로 TRO가 온열감수성에 미치는 영향을 연구하였다. 대상 및 방법: HeLa 세포를 $5{\mu}M$ TRO로 24시간 처치한 후 $42^{\circ}C$에서 1시간 동안 온열처리를 시행하였다. 세포 생존 분획은 clonogenic assay로 측정하였다. 단백질 발현의 변화는 Western blot으로 분석하였다. SOD와 카타라제의 활성도를 측정하였으며, reactive oxygen species (ROS) 는 2',7'-dichlorofluorescin diacetate와 dihydroethidium 를 사용하여 측정하였다. 결 과: 온열처리에 의해 감소된 생존분획이 TRO 전처치에 의해 증가하였다. 온열처리에의해 HSP 70의 발현은 증가하였으나 TRO 전 처치에 의해 감소되지는 않았다. SOD와 카타라제의 활성도가 각각 1.2배, 1.3배 증가하였다. 온열처리에 의해 ROS가 증가하였으며, 증가된 ROS는 TRO 전 처치에 의해 감소하였다. 결 론: TRO는 SOD와 카타라제의 활성도를 증가시키며 이는 온열에 의한 ROS를 감소시켜 결과적으로 온열감수성을 저하시킨다.

Keywords

References

  1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006;20:207-225 https://doi.org/10.1016/j.bpobgyn.2005.10.007
  2. Choi DH, Kim ES, Kim YH, et al. Literature analysis of radiotherapy in uterine cervix cancer for the processing of the patterns of care study in Korea. J Korean Soc Ther Radiol Oncol 2005;23:61-70
  3. Dewey WC, Hopwood LE, Sapareto SA, Gerweck LE. Cellular responses to combinations of hyperthermia and radiation. Radiology 1977;123:463-474 https://doi.org/10.1148/123.2.463
  4. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33-56 https://doi.org/10.1016/S1040-8428(01)00179-2
  5. van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355:1119-1125
  6. Vasanthan A, Mitsumori M, Park JH, et al. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys 2005;61:145-153 https://doi.org/10.1016/j.ijrobp.2004.04.057
  7. Franckena M, Lutgens LC, Koper PC, et al. Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients. Int J Radiat Oncol Biol Phys 2009;73:242-250 https://doi.org/10.1016/j.ijrobp.2008.03.072
  8. Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005;21:761-767 https://doi.org/10.1080/02656730500204487
  9. Kregel KC. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol 2002;92:2177-2186
  10. Arya R, Mallik M, Lakhotia SC. Heat shock genes: integrating cell survival and death. J Biosci 2007;32:595-610 https://doi.org/10.1007/s12038-007-0059-3
  11. Wu C. Heat shock transcription factors: structure and regulation. Annu Rev Cell Dev Biol 1995;11:441-469 https://doi.org/10.1146/annurev.cb.11.110195.002301
  12. Rossi A, Ciafre S, Balsamo M, Pierimarchi P, Santoro MG. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res 2006;66:7678-7685 https://doi.org/10.1158/0008-5472.CAN-05-4282
  13. Calderwood SK, Asea A. Targeting HSP70-induced thermotolerance for design of thermal sensitizers. Int J Hyperthermia 2002;18:597-608 https://doi.org/10.1080/0265673021000019666
  14. Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Int J Hyperthermia 1995;11:459-488 https://doi.org/10.3109/02656739509022483
  15. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45: 1661-1669 https://doi.org/10.2337/diabetes.45.12.1661
  16. Campbell MJ, Carlberg C, Koeffler HP. A role for the PPARgamma in cancer therapy. PPAR Res 2008;2008:314974
  17. Jung TI, Baek WK, Suh SI, et al. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Gynecol Oncol 2005;97:365-373 https://doi.org/10.1016/j.ygyno.2005.01.019
  18. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003;9:1-9
  19. Davies GF, Roesler WJ, Ovsenek N, Bharadwaj LA. Troglitazone reduces heat shock protein 70 content in primary rat hepatocytes by a ubiquitin proteasome independent mechanism. Pharmacol Res 2003;48:119-126
  20. Welbourne T, Su G, Coates G, Routh R, McCarthy K, Battarbee H. Troglitazone induces a cellular acidosis by inhibiting acid extrusion in cultured rat mesangial cells. Am J Physiol Regul Integr Comp Physiol 2002;282:R1600-R1607
  21. Friday E, Oliver R 3rd, Welbourne T, Turturro F. Role of epidermal growth factor receptor (EGFR)-signaling versus cellular acidosis via Na+/H+ exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7. Cell Physiol Biochem 2007;20:751-762 https://doi.org/10.1159/000110435
  22. Katschinski DM, Boos K, Schindler SG, Fandrey J. Pivotal role of reactive oxygen species as intracellular mediators of hyperthermia-induced apoptosis. J Biol Chem 2000;275:21094-21098 https://doi.org/10.1074/jbc.M001629200
  23. Zhao QL, Fujiwara Y, Kondo T. Mechanism of cell death induction by nitroxide and hyperthermia. Free Radic Biol Med 2006;40:1131-1143 https://doi.org/10.1016/j.freeradbiomed.2005.10.064
  24. Inoue I, Goto S, Matsunaga T, et al. The ligands/ activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001;50:3-11 https://doi.org/10.1053/meta.2001.19415
  25. Girnun GD, Domann FE, Moore SA, Robbins ME. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 2002;16:2793-2801 https://doi.org/10.1210/me.2002-0020
  26. Xu Y, Lu L, Greyson C, et al. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptorgamma activator in myocardial ischemia and reperfusion in pigs. Diabetes 2003;52:1187-1194 https://doi.org/10.2337/diabetes.52.5.1187
  27. Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004;337:1-13 https://doi.org/10.1016/j.gene.2004.04.032
  28. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-247 https://doi.org/10.1038/35041687
  29. Moncada S, Erusalimsky JD. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 2002;3:214-220 https://doi.org/10.1038/nrm762
  30. Gorman AM, Heavey B, Creagh E, Cotter TG, Samali A. Antioxidant-mediated inhibition of the heat shock response leads to apoptosis. FEBS Lett 1999;445:98-102 https://doi.org/10.1016/S0014-5793(99)00094-0
  31. He L, Lemasters JJ. Heat shock suppresses the permeability transition in rat liver mitochondria. J Biol Chem 2003;278:16755-16760 https://doi.org/10.1074/jbc.M300153200
  32. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000;2:469-475 https://doi.org/10.1038/35019501
  33. Bruey JM, Ducasse C, Bonniaud P, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000;2:645-652 https://doi.org/10.1038/35023595
  34. Wu L, Eftekharpour E, Davies GF, Roesler WJ, Juurlink BH. Troglitazone selectively inhibits glyoxalase I gene expression. Diabetologia 2001;44:2004-2012 https://doi.org/10.1007/s001250100004
  35. Davies GF, Khandelwal RL, Wu L, Juurlink BH, Roesler WJ. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism. Biochem Pharmacol 2001; 62:1071-1079 https://doi.org/10.1016/S0006-2952(01)00764-X
  36. Inoue I, Katayama S, Takahashi K, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 1997;235:113-116 https://doi.org/10.1006/bbrc.1997.6512